F. Hoffmann-La Roche Ltd.
Group Headquarters
Grenzacherstrasse 124
Basel
CH-4070
United States
Tel: 41-0-61-688-1111
Fax: 41-0-61-691-9391
Website: http://www.roche.com/
23 articles about F. Hoffmann-La Roche Ltd.
-
NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
12/8/2023
NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in first-line treatment of unresectable/advanced hepatocellular carcinoma (HCC).
-
Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for VABYSMO® (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
5/29/2023
Hoffmann-La Roche Limited announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for VABYSMO®, indicated for the treatment of neovascular age-related macular degeneration and diabetic macular edema,1 two of the leading causes of vision loss among Canadians.
-
VABYSMO® (faricimab injection) receives positive CADTH recommendation for the treatment of Diabetic Macular Edema (DME) in adults
11/3/2022
Hoffmann-La Roche Limited is pleased to announce that on October 31, 2022, the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee recommended VABYSMO® for public reimbursement.
-
Health Canada grants Interim Order authorization for casirivimab and imdevimab for the treatment of mild to moderate COVID-19
6/10/2021
Hoffmann-La Roche Limited announced that Health Canada has issued an Interim Order authorization for casirivimab and imdevimab, to be administered together, for the treatment of mild to moderate coronavirus disease 2019, confirmed by direct SARS-CoV-2 viral testing, in adults and adolescents who are at high-risk for progressing to hospitalization and/or death.
-
Health Canada approves Tecentriq® in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer(1)
9/27/2019
New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that significantly reduced the risk of disease progression by 38% compared with chemotherapy (nab-paclitaxel) alone2
-
F. Hoffmann-La Roche, Johnson & Johnson, and Novartis Compete for a Bigger Share of the Pharmaceuticals Industry, Reports Technavio
8/29/2019
The research reports examine the impact of the key players on a global level as well as in specific regions and countries
-
Major Players Operating in the Esophageal Cancer Drugs Market from 2019 to 2023 | Technavio
7/29/2019
Various combinations of chemotherapy drugs, along with targeted therapy, are necessary for the optimal treatment of esophageal cancer.
-
Top 5 Vendors in the Global Non-small Cell Lung Cancer Drugs Market 2019-2023 | Technavio
7/19/2019
Predictive biomarkers can reduce unnecessary treatment and adverse effects unlike chemotherapy and targeted therapies which may cause toxic effects.
-
Top 5 Vendors in the Bilirubin Blood Test Market From 2019 to 2023 | Technavio
7/18/2019
The incidence of drug-induced liver injuries is increasing at a significant rate across the world.
-
Top 5 Vendors in the Global Rickets Treatment Market 2019-2023 | Technavio
7/12/2019
There is a growing preference for OTC drugs as they can be bought without a prescription.
-
Top 5 Vendors in the Cancer Biologics Market from 2019 to 2023 | Technavio
7/10/2019
Vendors in the cancer biologics market have significantly increased investments for the development of cancer treating biologic molecules.
-
Top 5 Vendors in the Global Laryngeal Cancer Therapeutics Market 2019-2023 | Technavio
7/5/2019
The increase in smoking and the consumption of tobacco products have resulted in increased incidences of laryngeal cancer.
-
Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023 | Technavio
6/19/2019
According to Technavio Research Report "Parasitic Diseases Therapeutics Market by type and geographic regions is witnessed to grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”.
-
Health Canada approves TECENTRIQ® (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
5/29/2019
Data show this new option can help some metastatic NSCLC patients live significantly longer
-
BrightInsight Announces the Launch of a CE-marked Dosing Calculator for Emicizumab
5/23/2019
The development and distribution of the Dosing Calculator for emicizumab is sponsored by F. Hoffmann-La Roche.
-
Roche Presented Caprion Biosciences' Data on Targeted Mass Spectrometry for Clinical Proteomics
4/25/2019
Roche presented data demonstrating the use of GCP-compliant quantitative MRM mass spectrometry platform in clinical trials
-
F. Hoffmann-La Roche Ltd. Release: Combination Of Bevacizumab And Lomustine With First Recurrence Of Glioblastoma Prolongs PFS But Not OS
11/23/2015
-
2013 Facility of the Year Awards (FOYA) Winners Announced, Biogen Idec, Inc. (Massachusetts) and F. Hoffmann-La Roche Ltd. Among Them
2/4/2013
-
Acucela Inc. Appoints Former Bristol-Myers Squibb Company and F. Hoffmann-La Roche Ltd. Executive, Jaisim Shah, to the Company’s Board of Directors
8/3/2011
-
Aureus Pharma to Participate in a European Consortium for Drug Cardiac Toxicity
10/30/2008